These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23114986)

  • 1. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.
    Adair RA; Scott KJ; Fraser S; Errington-Mais F; Pandha H; Coffey M; Selby P; Cook GP; Vile R; Harrington KJ; Toogood G; Melcher AA
    Int J Cancer; 2013 May; 132(10):2327-38. PubMed ID: 23114986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
    Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
    Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
    Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
    Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
    Bhat R; Rommelaere J
    BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
    Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Samson A; Bentham MJ; Scott K; Nuovo G; Bloy A; Appleton E; Adair RA; Dave R; Peckham-Cooper A; Toogood G; Nagamori S; Coffey M; Vile R; Harrington K; Selby P; Errington-Mais F; Melcher A; Griffin S
    Gut; 2018 Mar; 67(3):562-573. PubMed ID: 27902444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
    Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune characterization of metastatic colorectal cancer patients post reovirus administration.
    Parakrama R; Fogel E; Chandy C; Augustine T; Coffey M; Tesfa L; Goel S; Maitra R
    BMC Cancer; 2020 Jun; 20(1):569. PubMed ID: 32552875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
    Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
    Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
    Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A
    Mol Cancer; 2011 Feb; 10():20. PubMed ID: 21338484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
    Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small extracellular vesicles carrying reovirus, tumor antigens, interferon-β, and damage-associated molecular patterns for efficient tumor treatment.
    Shuwari N; Inoue C; Ishigami I; Jingushi K; Kamiya M; Kawakami S; Tsujikawa K; Tachibana M; Mizuguchi H; Sakurai F
    J Control Release; 2024 Oct; 374():89-102. PubMed ID: 39122217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
    Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
    Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
    Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.
    El-Sherbiny YM; Holmes TD; Wetherill LF; Black EV; Wilson EB; Phillips SL; Scott GB; Adair RA; Dave R; Scott KJ; Morgan RS; Coffey M; Toogood GJ; Melcher AA; Cook GP
    Clin Exp Immunol; 2015 Apr; 180(1):98-107. PubMed ID: 25469725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of Oncolytic Reovirus by Cell Carriers.
    Ilett EJ
    Methods Mol Biol; 2020; 2058():229-236. PubMed ID: 31486041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Intensity Ultrasound as a Novel Strategy to Improve the Cytotoxic Effect of Oncolytic Reovirus on Colorectal Cancer Model Cells.
    Sharifi N; Soleimanjahi H; Mokhtari-Dizaji M; Banijamali RS; Elhamipour M; Karimi H
    Intervirology; 2022; 65(2):110-118. PubMed ID: 34510042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
    Parrish C; Scott GB; Migneco G; Scott KJ; Steele LP; Ilett E; West EJ; Hall K; Selby PJ; Buchanan D; Varghese A; Cragg MS; Coffey M; Hillmen P; Melcher AA; Errington-Mais F
    Leukemia; 2015 Sep; 29(9):1799-810. PubMed ID: 25814029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.
    Hall K; Scott KJ; Rose A; Desborough M; Harrington K; Pandha H; Parrish C; Vile R; Coffey M; Bowen D; Errington-Mais F; Melcher AA
    Biores Open Access; 2012 Jan; 1(1):3-15. PubMed ID: 23515241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.